Trials / Recruiting
RecruitingNCT07379827
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Effectiveness and Adverse-effect Switch Evaluation
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xanomeline and trospium chloride (KarXT) | According to the product label |
Timeline
- Start date
- 2026-02-26
- Primary completion
- 2028-06-20
- Completion
- 2028-06-20
- First posted
- 2026-02-02
- Last updated
- 2026-04-13
Locations
46 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07379827. Inclusion in this directory is not an endorsement.